테라젠이텍스

066700KOSDAQ의약품 제조업

67.3 / 100

Reference Date: 2026-04-13

Financial Score26.5 / 40

News Sentiment18.8 / 25

Momentum12.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but Operating Profit is on a declining trend. Rose 11.4% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

Teragen I-teks operates primarily in pharmaceutical manufacturing and sales, as well as genomic sequencing services. Its subsidiaries, Lead Pharm and Teragen Healthcare, specialize in specialty drug distribution and non-drug medical product sales, respectively. Additionally, Teragen Bio and overseas subsidiaries are expanding genomic analysis services into the Chinese market.

Number of Employees

222people

Average Salary

50.5M KRW

Score Calculation Basis

Detailed Financial Score

PER

9.86Industry Average 14.806.5Point

Lower than industry avg (good)

PBR

0.68Industry Average 1.045.5Point

Lower than industry avg (good)

ROE

8.11Industry Average 4.425.5Point

1.8x industry avg (good)

Debt Ratio

5.84Industry Average 11.986.5Point

Half of industry avg (excellent)

Trend 2023~20252.5 / 10 points

Revenue Growth Rate

2.5 / 3

Avg ▲10.7% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼5.1% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -0.4% (declining, 3yr)

Detailed News Sentiment

1 totalPositive 1Neutral 0Negative 0Average Sentiment Score 75

Positive
테라젠바이오, 작년 매출 105억원·영업이익 23.8% 개선…해외 진출...
테라젠이텍스의 자회사 테라젠바이오가 지난해 매출 105억원 달성, 영업적자 23.8% 개선, 당기순이익 흑자 전환을 기록했다.

Detailed Momentum

52-week position5.0Point

52w mid range (53%)

Current 2,920Won52-week high 3,31552-week low 2,460

1-month return5.0Point

1m +11.45% (rising)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

7 totalPositive 0Neutral 7Negative 0

Neutral사외이사의선임ㆍ해임또는중도퇴임에관한신고2026-04-03
Neutral정기주주총회결과2026-03-27
Neutral[첨부정정]사업보고서 (2025.12)2026-03-23
Neutral[첨부정정]감사보고서제출2026-03-23
Neutral사업보고서 (2025.12)2026-03-19